We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.94 | 1.07% | 88.64 | 88.62 | 88.70 | 88.64 | 87.63 | 87.68 | 51,271 | 08:05:08 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Sanofi SA on Friday said it has acquired Tidal Therapeutics, a preclinical-stage biotech startup using a novel mRNA-based approach for in-vivo reprogramming of immune cells, for an initial $160 million.
The Paris pharmaceutical giant said it could make up to an additional $310 in milestone payments as part of the deal, which it said expands its research capabilities in immuno-oncology and inflammatory diseases.
Sanofi said Tidal, based in Cambridge, Mass., uses a technology based on proprietary nanoparticles that deliver mRNA to reprogram immune cells inside the body. Tidal's current preclinical programs include in-vivo reprogramming of T-cells or other types of immune cells for cancer indications.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 09, 2021 14:16 ET (18:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
